Lili Chan

TL;DR: This study identified demographic, clinical, and hospital-level risk factors that may be associated with death in critically ill patients with COVID-19 and can facilitate the identification of medications and supportive therapies to improve outcomes.

TL;DR: This retrospective, observational study involved a review of data from electronic health records of patients aged ≥18 years with laboratory-confirmed COVID-19 admitted to the Mount Sinai Health System from February 27 to May 30, 2020 to describe the frequency of AKI and dialysis requirement, AKI recovery, and adjusted odds ratios with mortality.

TL;DR: Among critically ill patients with COVID-19 in this cohort study, the risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in the first 2 days of ICU admission compared with patients whose treatment did not include early use of tocilzumab, and the findings may be susceptible to unmeasured confounding.

TL;DR: The TTR V122I genetic variant was significantly associated with heart failure among individuals of African or Hispanic/Latino ancestry enrolled in 2 academic medical center-based biobanks.

TL;DR: In this article, the authors evaluated the incidence of venous thromboembolism (VTE) and major bleeding in critically ill patients with COVID-19 and examined the observational effect of early therapeutic anticoagulation on survival.